A Study of Extended Release Extended-release (ER) OROS Paliperidone Tolerability, as Compared to Immediate-release (IR)Risperidone, in Patients With Schizophrenia
Information source: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Schizophrenia
Intervention: extended-release (ER) OROS paliperidone (Drug)
Phase: Phase 1
Status: Completed
Sponsored by: Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Official(s) and/or principal investigator(s): Johnson & Johnson Pharmaceutical Research & Development, L.L. C. Clinical Trial, Study Director, Affiliation: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Summary
The purpose of this study is a noninferiority comparison of the orthostatic tolerability of
a dose of 12 mg extended-release (ER) OROS paliperidone with the current recommended initial
titration dose (2 mg) of immediate-release (IR) risperidone in patients with schizophrenia.
Other study objectives are 1) to compare the tolerability and safety of a clinically
equivalent fixed dose of ER OROS paliperidone with the currently recommended dose of
risperidone, 2) to compare the early tolerability of the 2 treatments with placebo, 3) to
compare tolerability of the 2 treatments, using a population pharmacokinetic/pharmacodynamic
(pop PK/PD) model, to 4) assess the relationship between genetic variability in drug
metabolizing enzymes and interindividual variability in plasma exposure to paliperidone or
risperidone within each treatment group.
Clinical Details
Official title: A Randomized, Double-blind, Placebo- and Active-controlled, Parallel-group, Phase 1 Study to Compare the Tolerability of OROS Paliperidone (Extended Release) With Immediate-release (IR) Risperidone in Subjects With Schizophrenia
Study design: Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment
Primary outcome: A non-inferiority comparison of the orthostatic tolerability of a higher initial dose of paliperidone OROS with the current recommended initial dose of risperidone in patients with schizophrenia
Secondary outcome: To compare the tolerability and safety of a clinically equivalent fixed dose of paliperidone OROS with the recommended dose of risperidone; early tolerability of the two formulations with placebo; tolerability using a pop PK/PD model
Detailed description:
This is a randomized, double-blind, placebo- and active-controlled, parallel group, Phase 1.
The study in patients with schizophrenia consists of a 1 week, open-label, placebo washout
period (Days - 7 to -1) and a 6 day double-blind treatment period during which patients will
receive 1 of 3 treatments: placebo on Day 1 and ER OROS paliperidone (12 mg) on Days 2 to 6,
ER OROS paliperidone (12 mg) on Days 1 to 6, or IR risperidone 2 mg on Day 1 and 4 mg on
Days 2 to 6. Safety and tolerability will be monitored throughout the study.. ER OROS
paliperidone (12 mg, oral) on Days 2 to 6, ER OROS paliperidone (12 mg, oral) on Days 1 to
6, or IR risperidone (oral) 2 mg on Day 1 and 4 mg on Days 2 to 6
Eligibility
Minimum age: 18 Years.
Maximum age: 65 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Willingness to spend 2 weeks as an in-patient during the washout and treatment period
- Currently treated with oral risperidone antipsychotic monotherapy for at least 1
month prior to screening
- DSM-IV diagnosis of schizophrenia (Patients with a diagnosis of schizophrenia
[paranoid type (295. 30), disorganized type (295. 10), catatonic type (295. 20),
undifferentiated type (295. 90), or residual type (295. 60)] as defined by DSM-IV
criteria
- Absence of acute exacerbation for a minimum of 6 months prior to screening
- Female patients must be postmenopausal for at least 1 year, surgically sterile, or
practicing an effective method of birth control (e. g., prescription oral
contraceptives, contraceptive injections, intrauterine device, double-barrier method,
contraceptive patch, male partner sterilization) before screening and throughout the
study, and have a negative urine pregnancy test at screening and baseline
- The patient is otherwise healthy on the basis of a physical examination, medical
history, electrocardiogram, and the results of blood biochemistry and hematology
tests and a urinalysis performed within 30 days of the start of the treatment period.
If the results of the biochemistry or hematology tests or the urinalysis testing are
not within the laboratory's reference ranges, the patient may be included only on
condition that the investigator judges that the deviations are not clinically
significant.
Exclusion Criteria:
- Involuntarily committed in-patients
- Patients who have received long-acting depot antipsychotic medication (discontinued
RISPERDAL CONSTA for less than 10 weeks or discontinued other depots for less than 2
cycles)
- Any significant history of cardiovascular disease: atrial fibrillation or flutter,
second and third degree heart block and equivalent, resting supraventricular
tachycardia (>100 beats per minute), unstable atherosclerotic heart disease, valvular
abnormality
- Body Mass Index > = 35 kg/m2 or a history of or current hypertension
- Use of disallowed concomitant therapy or patients likely to require prohibited
concomitant therapy during participation in the study
- Patients with a pacemaker
- Concomitant disease of the central nervous system that would bias the study
evaluations, e. g.
- stroke, brain tumor, Parkinson's disease, significant brain trauma, Alzheimer's
disease, epilepsy, multiple sclerosis, currently-treated migraine
- A DSM-IV Axis I diagnosis other than schizophrenia or with a DSM-IV diagnosis of
substance dependence within 6 months prior to screening evaluation (nicotine and
caffeine dependence are not exclusionary)
- Diabetes mellitus and/or repeated fasting blood glucose value during the washout
period >126 mg/dl and /or HbA1C > 7. 5%, hypothalamo-hypophyse dysfunction, Cushing,
Addison, thyrotoxicosis, or Anemia (as defined by hematocrit < 30%)
- Suicidal or homicidal ideation
- Positive drug screen at screening and at baseline
Locations and Contacts
Additional Information
A study of ER OROS paliperidone tolerability, as compared to IR risperidone, in patients with schizophrenia
Starting date: March 2003
Last updated: June 6, 2011
|